טוען...
AB 11. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with lung cancer and bone metastases
BACKGROUND: Breakthrough cancer pain (BTcP) represents an important clinical challenge in the care of patients with cancer. Oral opioids have traditionally been the only available drugs for BTcP. However, the onset and duration of action of oral opioids may not be suitable for treating many episodes...
שמור ב:
| Main Authors: | , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Pioneer Bioscience Publishing Company
2012
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3537363/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2072-1439.2012.s011 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|